AIM ImmunoTech Q4 EPS $(0.26) Misses $(0.15) Estimate, Sales $65.00K Beat $40.00K Estimate
$AIM
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
AIM ImmunoTech (AMEX:AIM) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.15) by 73.33 percent. This is a 188.89 percent decrease over losses of $(0.09) per share from the same period last year. The company reported quarterly sales of $65.00 thousand which beat the analyst consensus estimate of $40.00 thousand by 62.50 percent. This is a 16.07 percent increase over sales of $56.00 thousand the same period last year.